New pill could tame rare growth disorder without surgery

NCT ID NCT05192382

Terminated Disease control Sponsor: Crinetics Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study tests an oral drug called paltusotine in 111 adults with acromegaly, a condition causing abnormal growth due to high hormone levels. Participants are not currently on other treatments. The main goal is to see if the drug safely lowers insulin-like growth factor-1 (IGF-1) levels to normal, helping control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acromegaly

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACROMEGALY

Contacts and locations

Locations

Crinetics Study Site

Aurora, Colorado, 80045, United States
Crinetics Study Site

Boston, Massachusetts, 02114, United States
Crinetics Study Site

Columbus, Ohio, 43210, United States
Crinetics Study Site

Portland, Oregon, 97239, United States
Crinetics Study Site

Philadelphia, Pennsylvania, 19104, United States
Crinetics Study Site

Pittsburgh, Pennsylvania, 15213, United States
Crinetics Study Site

CABA, Buenos Aires, C1012AAR, Argentina
Crinetics Study Site

Buenos Aires, C1405BCH, Argentina
Crinetics Study Site

CABA, 1425, Argentina
Crinetics Study Site

CABA, C1199ABB, Argentina
Crinetics Study Site

Córdoba, X5000, Argentina
Crinetics Study Site

Fortaleza, Ceará, 60430-275, Brazil
Crinetics Study Site

Belo Horizonte, Minas Gerais, 30130100, Brazil
Crinetics Study Site

Curitiba, Paraná, 80030-110, Brazil
Crinetics Study Site

Botucatu, São Paulo, 18618-686, Brazil
Crinetics Study Site

Campinas, São Paulo, 13060-904, Brazil
Crinetics Study Site

Rio de Janeiro, 20231-092, Brazil
Crinetics Study Site

São Paulo, 05403-000, Brazil
Crinetics Study Site

São Paulo, 1228000, Brazil
Crinetics Study Site

Sofia, 1431, Bulgaria
Crinetics Study Site

Guangzhou, Guangdong, 510080, China
Crinetics Study Site

Shijiazhuang, Hebei, 050000, China
Crinetics Study Site

Zhengzhou, Henan, 450000, China
Crinetics Study Site

Wuhan, Hubei, 430030, China
Crinetics Study Site

Changsha, Hunan, 410003, China
Crinetics Study Site

Jinan, Shandong, 250063, China
Crinetics Study Site

Xi’an, Shanxi, 710032, China
Crinetics Study Site

Chengdu, Sichuan, 610041, China
Crinetics Study Site

Hangzhou, Zhejiang, 310009, China
Crinetics Study Site

Marseille, 13395, France
Crinetics Study Site

Pessac, 33604, France
Crinetics Study Site

Toulouse, 31400, France
Crinetics Study Site

Aachen, 52074, Germany
Crinetics Study Site

Berlin, 10117, Germany
Crinetics Study Site

München, 80336, Germany
Crinetics Study Site

München, 81667, Germany
Crinetics Study Site

Würzburg, 97080, Germany
Crinetics Study Site

Athens, 10676, Greece
Crinetics Study Site

Thessaloniki, 54642, Greece
Crinetics Study Site

Budapest, 1062, Hungary
Crinetics Study Site

Budapest, 1083, Hungary
Crinetics Study Site

Pécs, 7624, Hungary
Crinetics Study Site

Bangalore, Karnataka, 560054, India
Crinetics Study Site

Belagavi, Karnataka, 590010, India
Crinetics Study Site

Kochi, Kerala, 682041, India
Crinetics Study Site

Mumbai, Maharashtra, 400012, India
Crinetics Study Site

Chandigarh, 160012, India
Crinetics Study Site

Delhi, 110029, India
Crinetics Study Site

Petah Tikva, 4941492, Israel
Crinetics Study Site

Roma, 00168, Italy
Crinetics Study Site

Bydgoszcz, 85-605, Poland
Crinetics Study Site

Poznan, 60-355, Poland
Crinetics Study Site

Wroclaw, 50-367, Poland
Crinetics Study Site

Barcelona, 08035, Spain
Crinetics Study Site

London, EC1M 6BQ, United Kingdom
Crinetics Study Site (b)

Beijing, Beijing Municipality, 100730, China
Crinetics Study Site (b)

Athens, 11527, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.